A separate claims study of semaglutide examined medical spending among people who stayed on treatment. In this survey, total spending included prescriptions [1]. Overall spending was higher despite lower adjusted non-drug spending.
Who was included
The study used the U.S. Medical Expenditure Panel Survey. Its main analysis used 2019 and 2021, the two years with usable body mass index data. It included adults with obesity and at least one cardiometabolic risk factor [1].
The primary analysis covered a sample of 7,144 person-year records. Of those, 275 involved sustained GLP-1 use. A person-year is a record of one person for one year. Using only that year limits what the analysis can say about future spending.
How spending differed
Our comparison of national GLP-1 spending studies distinguishes drug spending from total medical spending. This study asks how overall spending differed between the groups it followed.
After adjustment, total spending was $6,483 higher per person-year. Non-drug spending was $2,586 lower. Acute care, which is part of non-drug spending, was $2,019 lower [1].
Before adjustment, non-drug spending was higher in the GLP-1 group. The reversal shows how much the comparison depended on accounting for differences between groups. Unmeasured differences could still affect the estimates [1].
What it says about a household budget
For a personal budget, a six-month cost estimate uses the prices and fees someone actually pays.
The survey found no statistically clear difference in out-of-pocket spending [1]. Its total spending estimate cannot tell a cash buyer what they will pay.